Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24

Core Insights - Profound Medical Corp. is set to present the first clinical outcomes from the Level 1 post-market CAPTAIN trial, comparing the TULSA Procedure™ with robotic radical prostatectomy for localized prostate cancer at the EAU 2026 Congress on March 13, 2026 [1][2] Company Overview - Profound Medical Corp. is a commercial-stage medical device company specializing in AI-powered, MRI-guided, incision-free therapies for ablation of diseased tissue [1][5] - The company's flagship platform, TULSA-PRO, allows for precise, incision-free prostate therapy, enabling real-time treatment confirmation and personalized strategies for prostate care [6] - Profound also offers Sonalleve, an MRI-guided therapy for non-surgical treatment of various conditions, including pain palliation for bone metastases and gynecologic issues [7] Upcoming Events - A press release summarizing the CAPTAIN presentation will be issued after the event, followed by an investor webinar at 11:30 a.m. EDT on March 13, 2026, where Dr. Klotz will discuss the clinical relevance of the data [3][4] - Profound management will participate in one-on-one investor meetings at the 38th Annual Roth Conference from March 22-24, 2026 [4] Market Approval - Profound's technologies, including TULSA-PRO and Sonalleve, are approved in major global markets, including the United States, Europe, Canada, and several other countries [8][9]